CURRICULUM VITAE

Name:	Diana C. Medgyesy
Present Title:	Medical Oncology and Hematology Physician Front Range Cancer Specialists Fort Collins, CO
Birth Date/Place:	5/22/67 Romania
Citizenship:	American
Office Address:	Front Range Cancer Specialists 2315 E. Harmony Road Suite 110 Fort Collins, CO 80528
Marital Status:	Married
Licensure/Active	Romania-1991 Wyoming – 6699A Colorado - 38494
Education:
1997- 2000	Medical Oncology and Hematology Fellowship University of Texas – M.D. Anderson Cancer Center, Houston, TX
1996-1997	PGY III Internal Medicine Yale University and New York Medical College St. Vincent’s Medical Center Bridgeport, CT
1995-1996	PGY II Internal Medicine Yale University and New York Medical College St. Vincent’s Medical Center Bridgeport, CT
1994-1995	PGY I Internal Medicine Yale University and New York Medical College St. Vincent’s Medical Center Bridgeport, CT
1992-1994	Volunteer at Stamford Hospital Stamford, CT Preparing for the USMLE Step I & II
1985-1991	M.D. Institute of Medicine and Pharmacology Timisoara, Romania
Specialty Boards:	American Board of Internal Medicine – 1997 American Board of Hematology – 2000 American Board of Medical Oncology - 2000
Society Memberships:	Member – American College of Physicians Member – American Society of Clinical Oncology Member – Larimer County Medical Society

Presentations:

• Polycystic Ovary Disease, aspects of differential diagnosis. 1991
• Meningeal carcinomatosis as an initial presentation of pancreatic carcinoma.
• Accuracy of VPAAR (Ventilation Power, A-a gradient and age related risk for mortality) in prediction the death risk in patients on ventilatory support. American College of Physicians Connecticut Chapter Meeting, 1997.
• Plasma Cell Disorders – Rocky Mountain Cancer Centers, Fort Collins, CO – September 2000.
• Overview of complications following blood and marrow transplantation for hematologic malignancies – Rocky Mountain Cancer Centers – Fort Collins, CO – October 2000.
• Breast Cancer – epidemiology, incidence and risk factors. Colorado State University, College of Veterinary Medicine and Biomedical Sciences, The Breast Cancer Affiliation Group, Fort Collins, CO – October 2000.
• Work-up of anemia in adults. Family Practice Residents, Poudre Valley Hospital, Fort Collins, CO – October 2000.
• Breast cancer – overview of prognostic and predictive factors. Perianesthesia nurses, Poudre Valley Hospital, Fort Collins, CO – November 2000.
• Gastrointestinal Stromal Tumors. Tumor Board, Poudre Valley Hospital, Fort Collins, CO – December 2000.
• Breast Cancer – treatment overview for the localized disease. Highplains Oncology Society Meeting – Windsor, CO, January 2001.
• Prevention of breast cancer with hormonal agents, are you a candidate? – Wonders of women symposia, Fort Collins, CO, February 2001.
• Work-up and treatment of the adult patient with a bleeding disorder. Family Practice residents, Poudre Valley Hospital – February 2001.
• Differential diagnosis of the monoclonal gammopathy and case discussion. Family Practice residents, Poudre Valley Hospital – March 2001.
• Oncologic emergencies. Poudre Valley Hospital Oncology nurses, Ft. Collins, CO – March 2001.
• Work-up and treatment of the adult patient with hypercoagulable state. Family Practice residents, Poudre Valley Hospital, Fort Collins, CO – April 2001.
• Endpoints of clinical trials in oncology. Medical staff of Poudre Valley Hospital, Ft. Collins, CO – May 2001
• “I can cope – overview of cancer treatment”. Poudre Valley Hospital, Ft. Collins, CO – June 2001
• Cancer screening. Larimer County Medical Society Public Forum. Lincoln Center, Ft. Collins, CO – September 2001
• Guidelines for the use of tumor markers in primary care practice. Family Practice residents. Fort Collins, CO – September 2001
• Breast Cancer Support Group – expectations and goals. Rocky Mountain Cancer Centers, Ft. Collins, CO – October 2001
• Ovarian Cancer Support Group – expectations and goals. Rocky Mountain Cancer Centers, Ft. Collins, CO – October 2001
• Her 2-neu positive metastatic breast cancer – treatment approaches. Breast Cancer Support Group. Fort Collins, CO – February 2002
• Breast cancer – are you at risk? Hach company. Loveland, CO – February 2002
• Breast cancer – treatment options for localized disease. Wonders of Women Symposium. Ft. Collins, CO – March 2002
• Taxol and Taxotere – management of the side effects. Breast Cancer Support Group. Ft. Collins, CO – March 2002
• You have completed the treatment for localized breast cancer: What next? – Breast Cancer Support Group – April 2002
• Faslodex, a new active agent against hormone sensitive breast cancer. In-service for the oncology nurses. Poudre Valley Hospital. Fort Collins, CO – April 2002
• Management of hot flushes. Breast and Ovarian Cancer Support Group. Fort Collins, CO – May 2002
• Work-up of anemia in adults. Family Practice Residents, Poudre Valley Hospital, Fort Collins, CO – October 2000.
• Overview of cancer treatment modalities. “I can cope “ series. Poudre Valley Hospital. Fort Collins, CO – June 2002
• Research studies: are you a candidate? Breast and Ovarian Cancer Support Group. Fort Collins, CO – September 2002
• Oncologic Emergencies. Oncology Nurses. Poudre Valley Hospital. Fort Collins, CO – January 2003
• Hormone Replacement Therapy – What your daughters need to know. Wonders on Women Symposium. Fort Collins, CO – March 2003
• Laboratory data related to the Oncology patient. Oncology Nurses. Poudre Valley Hospital. Fort Collins, CO – March 2003
• Treatment cancer modalities. “I can cope “ series. Poudre Valley Hospital. Fort Collins, CO – September 2003
• Understanding breast cancer treatment. Nurses at Front Range Cancer Specialists. Fort Collins, CO – February 2004
• Understanding ovarian cancer treatment. Nurses at Front Range Cancer Specialists. Fort Collins, CO – March 2004
• Understanding colon cancer treatment. Nurses at Front Range Cancer Specialists. Fort Collins, CO – April 2004
• Understanding lung cancer treatment. Nurses at Front Range Cancer Specialists. Fort Collins, CO – May 2004
• New strategies in the treatment of lymphoma. Poudre Valley Hospital. Fort Collins, CO – July 2004
• Overview of cancer treatment. “I can cope” series. Poudre Valley Hospital. Fort Collins, CO – September 2004
• New treatments of blood malignancies. “Meet the doctor” at “Light the night” walk. Leukemia and Lymphoma society. Fort Collins, CO – September 2004
• Eat well, stay healthy. Wonders of Women’s Symposium. Fort Collins, CO – March 2005
• Creating a community based state of the art Cancer Program. Poudre Valley Hospital Foundation Board of Directors. Fort Collins, CO – July 2005
• Understanding cancer research. Poudre Valley Hospital Foundation Board of Directors. Fort Collins, CO – August 2005
• Management of Early Breast Cancer. Radiologic Technologist ITV seminar. Greeley, CO – September 2005
• Adjuvant hormonal therapy for breast cancer. Grand Rounds at Casper Medical Center. Casper, WY – October 2005
• Updates in the hormonal therapy of localized breast cancer in postmenopausal women. Grand Rounds at St. Peter’s Hospital. Helena, MT – February 2006
• Understanding cancer treatments. “I can cope” series. Poudre Valley Hospital. Fort Collins, CO – March 2006
• Research Clinical Trials in Oncology. Poudre Valley Hopsital Foundation luncheon. Poudre Valley Hospital. Fort Collins, CO – April 2006
• “Light The Night” corporate breakfast. Fundraising event for the Leukemia Lymphoma society. Fort Collins, CO – June, 2006
• Components of a state of the art Community Cancer Program. Poudre Valley Hospital Foundation luncheon. Fort Collins, CO – October 2006
• Targeted Therapies for localized breast cancer. Cancer Symposium at Colorado Plains Medical Center. Fort Morgan, CO – November 2006
• Inside Breast Cancer: Targeted agents for the adjuvant treatment of Her2-neu positive breast cancer. Poudre Valley Hospital. Fort Collins, CO – December 2006
• Updates in the treatment of Breast Cancer. Breast Cancer Support Group. Loveland, CO – February, 2007

Publications:

• Validation of VPAAR Formula in prediction mortality and morbidity in patients on ventilator support. Chest, 1997.
• Pazdur R, Hoff PM, Medgyesy D Royce M, Brito RA: The oral fluorouracil prodrugs. Oncology Supplement 7, 48-51,1998.
• Hoff PM, Royce M, Medgyesy D, Brito R, Pazdur R: Oral fluoropyrmidines. Semin Oncol 26(6):640-6,1999.
• Pazdur R, Medgyesy DC, Hoff PM, Winn RJ, Dakhil DR, Moore DF, Scalzo A, Arbuck SG, Abbruzzese JL: Phase II trial of 9-aminocaptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for 3 weeks in metastatic colorectal carcinoma. Invest New Drugs 16(4):341-6,1998-99.
• Brito RA, Medgyesy D, Zukowski TH, Royce ME, Ravandi-Kashani R, Hoff PM, Pazdur R: Fluoropyrimidines: A critical review. Oncology 57 Suppl 1:2-8,1999.
• Medgyesy D, Wolff R, Putnam J, Ajani J: Small Cell carcinoma of the esophagus in the M.D. Anderson Cancer Center Experience. Cancer 88(2):262-7,2000.

Abstracts:

1. Royce M, Hoff P, Brito R, Matei C, Slaughter M, Medgyesy D, Lassere Y, Lee J, Coyle J, DeJagger RL, Pazdur R: Phase I trial of DX-8951f, a novel camptothecin Analogue administered by a 24-hour continuous infusion. Proc Am Soc Clin Oncol
   17:197a, 1998.
2. Medgyesy D, Pazdur R, Dakhil S, Moore D, Hoff P, Brito R, Matei C, Winn R, Abbruzzesse J: Phase II trial of 5-day continuous infusion of 9-amino camptothecin (9-AC) in advanced colorectal carcinomas. Proc Am Soc Clin Oncol 17:296a,1998.
3. Pazdur R, Hoff P, Slaughter M, Matei C, Brito R, Royce M, Medgyesy D, Lassere Y: Clinical development of UFT plus Leucovorin. Eighth International Congress on Anticancer Treatment, Paris, France, 1998.
4. Hoff P, Lassere Y, Royce M, Matei C, Slaughter M, Medgyesy D, Lee J, Coyle J, DeJagger RL, Pazdur R: Phase I study of the new camptothecin analogue DX-8951f administered by 24-hour continuous infusion. 10 th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, Netherlands, 65:246a, 1998.
5. Medgyesy D, Dakhil S, Moore D, Scalzo D, Hoff P, Abbruzzese J, Winn R, Pazdur R:
   A Phase I trial of a 5-day continuous infusion of 9-aminocamptothecin (9-AC) weekly for three weeks in patients with advanced colorectal carcinomas. 10 th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, Netherlands 67:254a,
   1998.
6. 6. Zukowski T, Carter S, Hoff P, Royce M, Medgyesy D, Brito R, Ravandi F, Lassere Y
   Newman R, Hausheer F, Pazdur R: Phase I and Pharmokinetic (PK) trial of the antifolate g-methylene-10-deazaaminopterin (MDAM) in patients with advanced solid tumors. Am Soc Clin Oncol 18:897a,1999.
7. 7. Royce M, Lassere Y, Hoff P, Brito R, Ravandi F, Medgyesy D, Zukowski T, Coyle J, DeJagger R, Pazdur R: DX-8951F: Phase I and pharmacokinetic study of a novel camptothecin anologue administered by 24-hour continuous infusion to patients with advanced solid tumors. Am Soc Clin Oncol 18:682a,1999.
8. Hoff P, Wenske C, Medgyesy D, Royce M, Brito R, Zukowski T, Ravande F, Kuritani J, Pazdur R: Phase I and pharmacokinetic (PK) study of the novel oral fluoropyrimidine, S-1. Am Soc Clin Oncol 18:665a, 1999. Medgyesy D, Wolff R, Putnam J, Ajani J: Small cell carcinoma of the esophagus in the M.D. Anderson Cancer Center Experience. Am Soc Clin Oncol 18:122a, 1999.
9. Hoff P, Abbruzzesse JL, Medgyesy D, Thomas M, Carter S: A phase II study of Xeloda (Capecitabine) in patients with colorectal cancer following progression on 5-FU therapy. Am Soc Clin Ocol 19:993a, 2000